Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Research

Intra-Cellular Therapies Files sNDA for CAPLYTA® as Adjunctive MDD Treatment

  • The Pharma Data
  • December 4, 2024

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company dedicated to central nervous system (CNS) therapeutics, has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food…

Read MoreIntra-Cellular Therapies Files sNDA for CAPLYTA® as Adjunctive MDD Treatment
  • Press Releases

Report from the 40th Polio IHR Emergency Committee Meeting

  • The Pharma Data
  • December 4, 2024

The World Health Organization (WHO) convened the 40th meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on November 6, 2024. The committee, composed of members, advisers,…

Read MoreReport from the 40th Polio IHR Emergency Committee Meeting
  • Research

Ono and Congruence Partner on Oncology Drug Discovery

  • The Pharma Data
  • December 4, 2024

Ono Pharmaceutical Co., Ltd. (Ono), headquartered in Osaka, Japan, has entered into a strategic collaboration agreement with Congruence Therapeutics, a biotechnology company based in Montreal, Canada. This partnership aims to…

Read MoreOno and Congruence Partner on Oncology Drug Discovery
  • Business

Revolution Medicines Prices $750M Public Offering

  • The Pharma Data
  • December 4, 2024

Revolution Medicines a clinical-stage oncology company focused on developing therapies for RAS-addicted cancers, has announced the pricing of its upsized public offering. The offering consists of 14,130,436 shares of common…

Read MoreRevolution Medicines Prices $750M Public Offering
  • Research

Daiichi Sankyo Showcases Oncology Progress at ESMO Asia, SABCS, and ASH

  • The Pharma Data
  • December 3, 2024

Daiichi Sankyo will present over 45 abstracts highlighting the progress across its oncology portfolio at the 2024 ESMO Asia Congress,San Antonio Breast Cancer Symposium and The American Society of Hematology…

Read MoreDaiichi Sankyo Showcases Oncology Progress at ESMO Asia, SABCS, and ASH
  • News

New Biovanta Study Demonstrates Highest Efficacy in Treating Common Cold

  • The Pharma Data
  • December 3, 2024

Common cold viruses cause substantial productivity losses and negatively impact overall well-being, with an estimated $40 billion lost annually in the United States alone. However, a new study published in…

Read MoreNew Biovanta Study Demonstrates Highest Efficacy in Treating Common Cold
  • Press Releases

Melinta Joins NHIA’s Future of Infusion Advisory Council

  • The Pharma Data
  • December 3, 2024

The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC, a biopharmaceutical company specializing in innovative therapies for acute and life-threatening conditions, are excited to announce Melinta’s membership in NHIA’s…

Read MoreMelinta Joins NHIA’s Future of Infusion Advisory Council
  • News

Revolution Medicines Shares Clinical Updates on RAS(ON) Inhibitor Portfolio

  • The Pharma Data
  • December 3, 2024

Revolution Medicines a clinical-stage oncology company developing targeted therapies for RAS-driven cancers, announced significant clinical updates from its RAS(ON) inhibitor portfolio. The data, presented during an investor webcast, focused on…

Read MoreRevolution Medicines Shares Clinical Updates on RAS(ON) Inhibitor Portfolio
  • News

Orion’s Nordic Pharmaceutical Manufacturing Ensures Security Across Europe

  • The Pharma Data
  • December 3, 2024

Orion ensures a steady supply of medicines by manufacturing them in its own facilities, while its subsidiary Fermion produces the active pharmaceutical ingredients (APIs) for these medicines. This integrated production…

Read MoreOrion’s Nordic Pharmaceutical Manufacturing Ensures Security Across Europe
  • Press Releases

CHMP Backs Palforzia for Treating Peanut Allergy in Toddlers

  • The Pharma Data
  • December 2, 2024

Stallergenes Greer, a leading biopharmaceutical company specializing in allergen immunotherapy (AIT), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…

Read MoreCHMP Backs Palforzia for Treating Peanut Allergy in Toddlers
  • Research

GE HealthCare to Fully Acquire Nihon Medi-Physics from Sumitomo Chemical

  • The Pharma Data
  • December 2, 2024

GE HealthCare (Nasdaq: GEHC) has reached an agreement to acquire the remaining 50% stake in Nihon Medi-Physics Co., Ltd. (NMP) from Sumitomo Chemical (TYO: 4005), giving it full ownership of…

Read MoreGE HealthCare to Fully Acquire Nihon Medi-Physics from Sumitomo Chemical
  • Research

Digital Twins: Advancing Clinical Research and Bridging Data Gaps

  • The Pharma Data
  • December 2, 2024

Projected to surpass $38 billion in value by 2032, artificial intelligence (AI) simulations—particularly digital twins—are reshaping the healthcare landscape. These virtual replicas of individuals possess an uncanny ability to replicate…

Read MoreDigital Twins: Advancing Clinical Research and Bridging Data Gaps
PrevNext
UK Biotech Day
Global Clinical
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Bio-Techne Expands COMET™ Suite with Modular Innovations to Advance Spatial Biology
  • WuXi Biologics Reports Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Innovation
  • Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Reach 100,000 Patients and Healthcare Workers in Two-Year Pilot
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.